Department of Clinical Nutrition, German Institute of Human Nutrition Potsdam-Rehbrücke, Arthur-Scheunert-Allee 114-116, Nuthetal, 14558, Germany.
Deutsches Zentrum für Diabetesforschung e.V., Geschäftsstelle am Helmholtz-Zentrum München, Ingolstädter Landstraße 1, Neuherberg, 85764, Germany.
Mol Nutr Food Res. 2021 Jun;65(12):e2000991. doi: 10.1002/mnfr.202000991. Epub 2021 May 16.
The Optimal Fibre Trial (OptiFiT) investigates metabolic effects of insoluble cereal fibre in subjects with impaired glucose tolerance (IGT), showing moderate glycemic and anti-inflammatory benefits, especially in subjects with an obesity-related phenotype. An OptiFiT sub-group is analysed for effects on body fat distribution.
180 participants with IGT receive a blinded, randomized supplementation with insoluble cereal fibre or placebo for 2 years. Once a year, all subjects undergo fasting blood sampling, oral glucose tolerance test, and anthropometric measurements. A subgroup (n=47) also received magnetic resonance imaging and spectroscopy for quantification of adipose tissue distribution and liver fat content. We compared MR, metabolic and inflammatory outcomes between fibre and placebo group metabolism and inflammation. Visceral and non-visceral fat, fasting glucose, HbA1c, fasting insulin, insulin resistance, and uric acid decrease only in the fibre group, mirroring effects of the entire cohort. However, after adjustment for weight loss, there are no significant between-group differences. There is a statistical trend for fibre-driven liver fat reduction in subjects with confirmed non-alcoholic fatty liver disease (NAFLD; n = 19).
Data and evidence on beneficial effects of insoluble cereal fibre on visceral and hepatic fatstorage is limited, but warrants further research. Targeted trials are required.
OptiFiT（最佳纤维试验）研究了不溶性谷物纤维对糖耐量受损（IGT）患者的代谢影响，结果显示其具有适度的降血糖和抗炎作用，尤其对肥胖相关表型的患者效果更为明显。OptiFiT 的一个亚组分析了其对体脂分布的影响。
180 名 IGT 患者接受了为期 2 年的不溶性谷物纤维或安慰剂的双盲随机分组。每年，所有患者都接受空腹采血、口服葡萄糖耐量试验和人体测量。一个亚组（n=47）还接受了磁共振成像和光谱分析，以定量评估脂肪组织分布和肝内脂肪含量。我们比较了纤维组和安慰剂组的代谢和炎症结果。仅在纤维组中观察到内脏和非内脏脂肪、空腹血糖、HbA1c、空腹胰岛素、胰岛素抵抗和尿酸降低，这与整个队列的结果一致。然而，在调整体重减轻后，两组之间没有显著差异。在已确诊的非酒精性脂肪性肝病（NAFLD；n=19）患者中，纤维组有降低肝脂肪的统计学趋势。
关于不溶性谷物纤维对内脏和肝脏脂肪储存有益影响的数据和证据有限，但值得进一步研究。需要开展有针对性的试验。
